Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name:	us-gaap_AssetsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_AssetsFairValueDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name:	us-gaap_CashAndCashEquivalentsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Fair value as of the balance sheet date of all foreign currency derivatives designated as cash flow hedging instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-Subparagraph (a),(b),(c)(1)

-URI http://asc.fasb.org/extlink&oid=35706170&loc=SL5624163-113959

+ Details

Name:	us-gaap_ForeignCurrencyCashFlowHedgeDerivativeAtFairValueNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Fair value portion of contractual obligation to pay money on demand or on fixed or determinable dates.

+ References

No definition available.

+ Details

Name:	us-gaap_LoansPayableFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.4)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name:	us-gaap_MarketableSecurities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Variable Interest Entity, Consolidated, Carrying Amount, Cash and Cash Equivalents

+ References

No definition available.

+ Details

Name:	vrtx_VariableInterestEntityConsolidatedCarryingAmountCashandCashEquivalents
Namespace Prefix:	vrtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Fair Value Measurements (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Financial assets carried at fair value:
Fair value foreign currency forward contracts	$ 2,011,000	$ 0
Level 3
Financial assets carried at fair value:
Fair value of the Term Loan	294,800,000
Recurring basis
Financial assets carried at fair value:
Total	1,054,389,000
Recurring basis \| Money market funds
Financial assets carried at fair value:
Cash equivalents:	290,531,000
Recurring basis \| Government-sponsored enterprise securities
Financial assets carried at fair value:
Marketable securities:	463,750,000
Recurring basis \| Commercial paper
Financial assets carried at fair value:
Marketable securities:	51,746,000
Recurring basis \| Corporate debt securities
Financial assets carried at fair value:
Marketable securities:	246,351,000
Recurring basis \| Level 1
Financial assets carried at fair value:
Total	754,281,000
Recurring basis \| Level 1 \| Money market funds
Financial assets carried at fair value:
Cash equivalents:	290,531,000
Recurring basis \| Level 1 \| Government-sponsored enterprise securities
Financial assets carried at fair value:
Marketable securities:	463,750,000
Recurring basis \| Level 1 \| Commercial paper
Financial assets carried at fair value:
Marketable securities:	0
Recurring basis \| Level 1 \| Corporate debt securities
Financial assets carried at fair value:
Marketable securities:	0
Recurring basis \| Level 2
Financial assets carried at fair value:
Total	300,108,000
Recurring basis \| Level 2 \| Money market funds
Financial assets carried at fair value:
Cash equivalents:	0
Recurring basis \| Level 2 \| Government-sponsored enterprise securities
Financial assets carried at fair value:
Marketable securities:	0
Recurring basis \| Level 2 \| Commercial paper
Financial assets carried at fair value:
Marketable securities:	51,746,000
Recurring basis \| Level 2 \| Corporate debt securities
Financial assets carried at fair value:
Marketable securities:	246,351,000
Recurring basis \| Level 3
Financial assets carried at fair value:
Total	0
Recurring basis \| Level 3 \| Money market funds
Financial assets carried at fair value:
Cash equivalents:	0
Recurring basis \| Level 3 \| Government-sponsored enterprise securities
Financial assets carried at fair value:
Marketable securities:	0
Recurring basis \| Level 3 \| Commercial paper
Financial assets carried at fair value:
Marketable securities:	0
Recurring basis \| Level 3 \| Corporate debt securities
Financial assets carried at fair value:
Marketable securities:	0
Foreign currency forward contracts
Financial assets carried at fair value:
Fair value foreign currency forward contracts	2,011,000	(23,000)
Foreign currency forward contracts \| Recurring basis
Financial assets carried at fair value:
Fair value foreign currency forward contracts	2,011,000
Foreign currency forward contracts \| Recurring basis \| Level 1
Financial assets carried at fair value:
Fair value foreign currency forward contracts	0
Foreign currency forward contracts \| Recurring basis \| Level 2
Financial assets carried at fair value:
Fair value foreign currency forward contracts	2,011,000
Foreign currency forward contracts \| Recurring basis \| Level 3
Financial assets carried at fair value:
Fair value foreign currency forward contracts	0
Variable Interest Entity, Primary Beneficiary \| BioAxone Biosciences, Inc
Financial assets carried at fair value:
Cash and cash equivalents	8,400,000
Variable Interest Entity, Primary Beneficiary \| BioAxone Biosciences, Inc \| Level 1
Financial assets carried at fair value:
Cash and cash equivalents	$ 8,400,000